Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making
Therapy decision-making in prostate cancer has traditionally been limited to clinical, histopathological, and radiological variables that does not take into account the varying biology of prostate cancer manifestations. It is well-known that disease stratification tools we use in our clinics every...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2024-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/467287 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850166936836505600 |
|---|---|
| author | Antonela Njavro Jure Murgić Blanka Jakšić Marin Prpić Angela Prgomet Sečan Dora Franceschi Marija Miletić Slaven Ovčariček Adelina Hrkač Ivan Šamija Monika Ulamec Marijana Jazvić Pero Bokarica Igor Tomašković Ana Fröbe |
| author_facet | Antonela Njavro Jure Murgić Blanka Jakšić Marin Prpić Angela Prgomet Sečan Dora Franceschi Marija Miletić Slaven Ovčariček Adelina Hrkač Ivan Šamija Monika Ulamec Marijana Jazvić Pero Bokarica Igor Tomašković Ana Fröbe |
| author_sort | Antonela Njavro |
| collection | DOAJ |
| description | Therapy decision-making in prostate cancer has traditionally been limited to clinical,
histopathological, and radiological variables that does not take into account the varying biology of prostate
cancer manifestations. It is well-known that disease stratification tools we use in our clinics every day
to customize therapy choices for individual patients with prostate cancer fail to capture and address the
wide ranges of observed disease clinical courses. Prostate cancer is characterized by significant intra- and
interpatient heterogeneity that makes this disease unique and extremely variable. The advent of affordable
next-generation genomic sequencing techniques has allowed the incorporation of these data into clinical
research, with enormous potential to aid clinical care in the future. The optimal goal of prostate cancer
treatment is to personalize treatment specific to a patient’s unique clinic-genomic phenotypes. We may
thus potentially avoid overtreatment in patients harboring less aggressive disease and undertreatment in
patients harboring more aggressive disease. Currently, we lack that ability if we rely only on clinical stratification
tools such as the NCCN model, CAPRA scoring, and D’Amico classification. It may be the
case that prostate cancer genomics hold the key to understanding and predicting the response to crucial
treatment modalities in prostate cancer: androgen deprivation therapy, radiotherapy, and next-generation
androgen pathway inhibition therapy. Currently, there are many open questions about how to use these
therapies optimally in individual patients. In this freeform narrative review, we summarize the literature
and current clinical practice of biomarkers in prostate cancer, specifically focusing on genomic tests utilized
in radiotherapy management and/or adjunctive therapies given with radiotherapy. |
| format | Article |
| id | doaj-art-363af51398f7467580c0b8a682ec9e38 |
| institution | OA Journals |
| issn | 0353-9466 1333-9451 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Sestre Milosrdnice University hospital, Institute of Clinical Medical Research |
| record_format | Article |
| series | Acta Clinica Croatica |
| spelling | doaj-art-363af51398f7467580c0b8a682ec9e382025-08-20T02:21:18ZengSestre Milosrdnice University hospital, Institute of Clinical Medical ResearchActa Clinica Croatica0353-94661333-94512024-01-0163.Supplement 2717510.20471/acc.2024.63.s2.11Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-MakingAntonela Njavro0Jure Murgić1Blanka Jakšić2Marin Prpić3Angela Prgomet Sečan4Dora Franceschi5Marija Miletić6Slaven Ovčariček7Adelina Hrkač8Ivan Šamija9Monika Ulamec10Marijana Jazvić11Pero Bokarica12Igor Tomašković13Ana Fröbe14Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Urology, Clinical Hospital Sveti Duh, Zagreb, CroatiaDepartment of Urology, Clinical Hospital Sveti Duh, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; Department of Immunology, School of Dental Medicine, University of Zagreb, Zagreb, CroatiaDepartment of Pathology and Cytology “Ljudevit Jurak”, University Hospital Center Sestre milosrdnice, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Urology, Clinical Hospital Sveti Duh, Zagreb, CroatiaDepartment of Urology, University Hospital Center Sestre milosrdnice, Zagreb, Croatia; School of Medicine, Josip Juraj Strossmayer University, Osijek, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, CroatiaTherapy decision-making in prostate cancer has traditionally been limited to clinical, histopathological, and radiological variables that does not take into account the varying biology of prostate cancer manifestations. It is well-known that disease stratification tools we use in our clinics every day to customize therapy choices for individual patients with prostate cancer fail to capture and address the wide ranges of observed disease clinical courses. Prostate cancer is characterized by significant intra- and interpatient heterogeneity that makes this disease unique and extremely variable. The advent of affordable next-generation genomic sequencing techniques has allowed the incorporation of these data into clinical research, with enormous potential to aid clinical care in the future. The optimal goal of prostate cancer treatment is to personalize treatment specific to a patient’s unique clinic-genomic phenotypes. We may thus potentially avoid overtreatment in patients harboring less aggressive disease and undertreatment in patients harboring more aggressive disease. Currently, we lack that ability if we rely only on clinical stratification tools such as the NCCN model, CAPRA scoring, and D’Amico classification. It may be the case that prostate cancer genomics hold the key to understanding and predicting the response to crucial treatment modalities in prostate cancer: androgen deprivation therapy, radiotherapy, and next-generation androgen pathway inhibition therapy. Currently, there are many open questions about how to use these therapies optimally in individual patients. In this freeform narrative review, we summarize the literature and current clinical practice of biomarkers in prostate cancer, specifically focusing on genomic tests utilized in radiotherapy management and/or adjunctive therapies given with radiotherapy.https://hrcak.srce.hr/file/467287BiomarkersProstate cancerRisk stratificationGenomicsRadiotherapyAndrogen deprivation therapy |
| spellingShingle | Antonela Njavro Jure Murgić Blanka Jakšić Marin Prpić Angela Prgomet Sečan Dora Franceschi Marija Miletić Slaven Ovčariček Adelina Hrkač Ivan Šamija Monika Ulamec Marijana Jazvić Pero Bokarica Igor Tomašković Ana Fröbe Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making Acta Clinica Croatica Biomarkers Prostate cancer Risk stratification Genomics Radiotherapy Androgen deprivation therapy |
| title | Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making |
| title_full | Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making |
| title_fullStr | Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making |
| title_full_unstemmed | Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making |
| title_short | Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making |
| title_sort | biomarkers and personalized medicine in prostate cancer advent of precision oncology in radio therapy decision making |
| topic | Biomarkers Prostate cancer Risk stratification Genomics Radiotherapy Androgen deprivation therapy |
| url | https://hrcak.srce.hr/file/467287 |
| work_keys_str_mv | AT antonelanjavro biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT juremurgic biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT blankajaksic biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT marinprpic biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT angelaprgometsecan biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT dorafranceschi biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT marijamiletic biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT slavenovcaricek biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT adelinahrkac biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT ivansamija biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT monikaulamec biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT marijanajazvic biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT perobokarica biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT igortomaskovic biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking AT anafrobe biomarkersandpersonalizedmedicineinprostatecanceradventofprecisiononcologyinradiotherapydecisionmaking |